Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.
Kevin Young XuAlex K GertnerShelly F GreenfieldArthur Robin WilliamsRichard A GruczaPublished in: Addiction science & clinical practice (2024)
Buprenorphine discontinuation is high across outpatient PCP, psychiatry, and SUD treatment facility settings, with potentially lower treatment retention among Medicaid enrollees receiving care from SUD facilities and PCPs.